1.29
+10.78%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ALX Oncology Holdings
From its filings with the US Securities and Exchange Commission
ALX Oncology Holdings is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ALXO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2022, it reported revenue of $0.
We are a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. Our clinical pipeline includes two clinical-stage product candidates, the CD47 blocker evorpacept and an epidermal growth factor receptor (EGFR)-targeted antibody drug candidate (ADC) ALX2004. Our lead product candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built for patients whose cancer over-expresses CD47. Evorpacept is currently being evaluated in combination with trastuzumab and chemotherapy in patients with metastatic HER2-positive breast cancer in the Phase 2 ASPEN-09-Breast clinical trial and is also being studied in clinical trials with other targeted anti-cancer antibodies. Cancer cells leverage CD47, a cell surface protein, as a “don’t eat me” signal to evade macrophage phagocytosis. We are developing evorpacept to be a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Our second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action entered into a Phase 1 clinical trial in August 2025.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jul 2020
- Employees
- 43
- Website
- alxoncology.com ↗
- Head office
- 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Corey GoodmanExecutive Chairman of the Board, since 2015$216,846
- Mr. Jason LettmannChief Executive Officer, Director, since 2020$6.6m
- Mr. Harish ShantharamChief Financial Officer
- Ms. Shelly PintoSenior Vice President - Finance, Chief Accounting Officer$1.5m
- Dr. Barbara KlenckeChief Medical Officer, since 2025
- Dr. Alan SandlerDirector, since 2024$96,639
- Dr. Daniel CurranIndependent Director
- Mr. Scott GarlandIndependent Director$182,828
- Ms. Rekha HemrajaniIndependent Director$186,828
- Mr. Chris TakimotoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 49
- Social
- 87
- Governance
- 15
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ALX Oncology Holdings Inc has several notable strengths that contribute to its success and competitive advantage in the oncology industry. These strengths include:
Weaknesses
- Despite its strengths, ALX Oncology Holdings Inc also encounters some weaknesses that could hinder its growth and market positioning. These weaknesses include:
Opportunities
- ALX Oncology Holdings Inc can leverage various opportunities to further strengthen its market position and achieve business growth. These opportunities include:
Threats
- ALX Oncology Holdings Inc faces several threats that could impact its business operations and overall success. Some of the major threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.